International Journal of

Current Pharmaceutical Review and Research

e-ISSN: 0976 822X

NMC Approved

Peer Review Journal

Disclimer: Scopus and Crossref are registered trademark of respective companies.

This journal is member of Crossref. 

1. Analysis of performance indicators applied in a university hospital conveniated to the Brazilian Hospital Services Company.
Júlia Lorena Marques Gurgel, Hélio Roberto Hékis, Rafael Monteiro de Vasconcelos, Ricardo Alexsandro de Medeiros Valentim, Custódio Leopoldino de Brito Guerra Neto, Amália Cinthia Meneses Rêgo, Irami Araújo-Filho
Introduction: In Brazil, university hospitals have fundamental importance in the evolution of the Unified Health System (SUS) and in several areas that favor the improvement of the health conditions of the population. Thus, this article aims to analyze performance indicators of the Onofre Lopes Universitary Hospital, located in the northeast region of the country, before and after joining the management contract with the Brazilian Hospital Services Company (EBSERH). Methods: In order to perform this study, the authors selected performance indicators in hospital organizations and analyzed the comparative of the bienniums 2011-2012 and 2014-2015, based on the performance index matrix. The 32 indicators are organized in terms of structure and results, and in the categories: installations, human resources, revenue, production, productivity, quality, costs and teaching/research/extension. Results: The results show better performance of the indicators in the biennium 2014-2015. The authors attribute this evolution of the performance indexes to the expansion and reorganization of the work team, to the increase in revenue, to structural reforms and to the provision of new services to the population. Conclusion: The small number of studies that relate the results of the indicators in a periodic comparison of the same hospital is noticeable. Therefore, is essential the monitoring, analysis and dissemination of these indicators.

2. Larvicidal Activity of Various Extracts of Selected Plants Against the Dengue Vector Larvae
Shibu George
Vector born diseases, especially mosquito born diseases are increasing day by day due to environmental changes. This may adversely affect the socio-economic realms of the developing countries. One of the best remedies to overcome mosquito born diseases is to reduce the mosquito populations by using insecticides and larvicides. However, the use of chemical insecticides has some disadvantages. They may increase the chance of insecticide resistance and environmental pollutions. As an alternative, plant based drugs are preferred because they are safer than synthetic insecticides and larvicides. In this study, twelve different plants collected from the Kuttand areas of Alappuzha District of Kerala State were used for studying their larvicidal activity against 3rd and 4th instar larvae of dengue vector, the Aedes sp. The larvicidal activity was assessed by standard procedure, as described by the WHO, but with a slight modification. The results of the study showed that among the various extracts tested, only the methanolic extract of flowers of Ipomoea cairica was powerful to inhibit the growth of all the tested larvae (100%) at a concentration of 0.4 mg/ml. Its methanolic extracts were also showed 95% and 83% of larvicidal activities at a concentration of 0.2 mg/ml and 0.1 mg/ml respectively. Previous studies showed that the leaves of Ipomoea cairica possess larvicidal activity. But, this study suggests that the methanol extracts of flowers of Ipomoea cairica possess promising larvicidal activity against the dengue vector larvae of Aedes species.

3. Formulation And In Vitro Evaluation Of Controlled Release Transdermal Drug Delivery System Of Simvastatin A Model Hypocholesterolemia Drug
Mohapatra P K, Nagalakshmi C H, Tomer V,Gupta M K, Varma H C, Singh N, Sahoo S
The intention of this research work was to develop a matrix-type transdermal drug delivery system (TDDS) containing simvastatin an antilipidemic drug with different ratios of hydrophilic HPMC K100M and hydrophobic Eudragit RL100 & Eudragit RS100 polymers with surfactant Tween 80 and plasticizer glycerin by the solvent evaporation technique. The prepared films were evaluated for physicochemical properties. Matrix films were evaluated for their physicochemical characterization followed by in-vitro evaluation. The drug released rate was found to be increased when the concentration of the polymer decreases. The release rates by using three polymers are shown that the HPMC K100M showed faster release than Eudragit RL100 and Eudragit RS100 because due to hydrophilicity. Compared between Eudragit RL100 and Eudragit RS100, the release rate was slightly faster found in Eudragit RL100. The evaluation studies were carried out known as percentage moisture content, percentage moisture uptake, folding endurance, thickness, weight variation, physical appearance, UV-Visible spectrophotometer, FTIR study and quantitative estimation of the drug. It was shown by all the observations that the antilipidemic drug simvastatin could serve as an appropriate candidate for TDDS that can improve the bioavailability.

4. GDUFA: Implementation And The Latest Amendments
M.P Venkatesh, Thaikadan Soorya Sukumaran
The law which is designed to fasten the delivery of safer and effective generic drugs to public and improve on the predictability of the review process is called the Generic Drug User fee Act (GDUFA). GDUFA made sure that the ones participating in the U.S generic drug system meets the quality requirements of U.S and also increased the timely access to high quality generic drugs in lower cost to the American purchasers. Before the implementation of GDUFA due to the limited resources the FDA was not able to manage the review of increasing number of applications. But after the enactment of GDUFA User Fee Amendments in the year 2012 the FDA started getting funds from the generic drug industry in order to ensure that the public receives safe and effective generic drugs at all times. Further, to facilitate the timely access to reasonable generic medicines and to report the issues related to GDUFA, GDUFA II was signed into law on August 18, 2017. Then the FDA agreed to review procedures and goals for the preparation and conduct of post-Close Response Letter meetings.

Impact Factor: 1.041

NMC Approved Embase Indexed

This journal is peer Reviewed Journal